news High-throughput screening reveals 21 drugs with activity against COVID-19 28 July 2020 | By Victoria Rees (Drug Target Review) After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
news Could the Nsp1 protein be a novel drug target for COVID-19? 20 July 2020 | By Hannah Balfour (Drug Target Review) A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
news Genomics England launches next-generation research platform 7 July 2020 | By Hannah Balfour (Drug Target Review) The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
news Six molecular targets for COVID-19 identified by researchers 30 June 2020 | By Victoria Rees (Drug Target Review) A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
news X-rays reveal structure of SARS-CoV-2 protease at room temperature 29 June 2020 | By Victoria Rees (Drug Target Review) Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
news Study identifies 68 genes associated with risk of severe COVID-19 26 June 2020 | By Victoria Rees (Drug Target Review) A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
news Promising COVID-19 drug candidate identified by virtual screening 25 June 2020 | By Victoria Rees (Drug Target Review) After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
news Open source all-atom model of entire COVID-19 S protein released 23 June 2020 | By Victoria Rees (Drug Target Review) Researchers have developed a video and model-building programme for other scientists to build full-length COVID-19 S protein models.
news N terminal domain of S protein revealed as antibody target for COVID-19 23 June 2020 | By Victoria Rees (Drug Target Review) An antibody with high neutralising potency against SARS-CoV-2 that binds to the N terminal domain of the Spike protein has been identified by a team researching COVID-19 therapeutics.
news Method to convert any mouse into COVID-19 model made available to researchers 22 June 2020 | By Victoria Rees (Drug Target Review) Researchers who reported that delivering the human ACE2 protein into mouse airway cells creates COVID-19 models have released their findings to allow other scientists to make their own models.
news Biomarker suggests COVID-19 could cause brain injury in patients 19 June 2020 | By Victoria Rees (Drug Target Review) Researchers have found that a neurofilament named NfL is heightened in COVID-19 patients who require ventilator treatment, so could serve as a biomarker for the disease.
news Screening reveals nelfinavir and amodiaquine combat COVID-19 in cell cultures 18 June 2020 | By Victoria Rees (Drug Target Review) Researchers who screened 136 broad-spectrum antivirals identified six with the most activity against COVID-19 and an optimum combination of two to fight the virus.
news Online tool allows researchers to track genetic structure of SARS-CoV-2 16 June 2020 | By Victoria Rees (Drug Target Review) An artificial intelligence platform available online has been designed to help researchers track the genetics of SARS-CoV-2 as it moves from person to person.
news SARS-CoV-2 immunodominant epitopes identified as vaccine candidates 12 June 2020 | By Victoria Rees (Drug Target Review) Researchers have analysed the SARS-CoV-2 proteome to reveal seven promising immunodominant epitopes that could aid in the development of a COVID-19 vaccine.
news Protease inhibitors could be highly effective against SARS-CoV-2 10 June 2020 | By Hannah Balfour (Drug Target Review) Researchers reveal the main protease (Mpro) of SARS-CoV-2 is highly sensitive to disruption, therefore Mpro inhibitors could be a potential COVID-19 therapeutic.
